Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
- Kindler, Hedy Lee
- Niedzwiecki, Donna
- Hollis, Donna
- Sutherland, Susan
- Schrag, Deborah
- Hurwitz, Herbert
- Innocenti, Federico
- Mulcahy, Mary Frances
- O'Reilly, Eileen
- Wozniak, Timothy F.
- Picus, Joel
- Bhargava, Pankaj
- Mayer, Robert J.
- Schilsky, Richard L.
- Goldberg, Richard M.
Publication date
January 2010
DOIAbstract
The combination of gemcitabine plus bevacizumab produced a 21% response rate and a median survival of 8.8 months in a multicenter phase II trial in patients with metastatic pancreatic cancer. These encouraging data led Cancer and Leukemia Group B (CALGB) to conduct a double-blind, placebo-controlled, randomized phase III trial of gemcitabine/bevacizumab versus gemcitabine/placebo in advanced pancreatic cancer patients
Add to ORKG